{"transactions":[{"id":1033131,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-24T20:16:32.000Z","date":"2025-09-22","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date."}],"balance_after":18000,"derivative":{"exercise_price":23.67,"expiration_date":"2035-09-21","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001864112-25-000004","document":"form4-09242025_080928.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000186411225000004/form4-09242025_080928.xml","form_type":"4"}},{"id":1080728,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T21:15:24.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":526000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Stock Option having an exercise price equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and the Milestone Payment (each such option, a \"Closing Date Contingent Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Closing Date Contingent Option, and each holder of such Closing Date Contingent Option is entitled to receive (without interest) an amount in cash (less any applicable tax withholdings) equal to the product of (i) the total number of shares of the Issuer's Common Stock subject to such Closing Date Contingent Option immediately prior to the Effective Time multiplied by (ii) the cash payment a holder of one CVR would receive, and when such payments are made to the holders of CVRs (without regard to vesting);"},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(continued from footnote 6) provided that each such Closing Date Contingent Option shall only receive the excess of the sum of (x) the Cash Consideration plus (y) the Milestone Payment over the applicable exercise price of such Closing Date Contingent Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Stock Option having an exercise price equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and the Milestone Payment (each such option, a \"Closing Date Contingent Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Closing Date Contingent Option, and each holder of such Closing Date Contingent Option is entitled to receive (without interest) an amount in cash (less any applicable tax withholdings) equal to the product of (i) the total number of shares of the Issuer's Common Stock subject to such Closing Date Contingent Option immediately prior to the Effective Time multiplied by (ii) the cash payment a holder of one CVR would receive, and when such payments are made to the holders of CVRs (without regard to vesting);"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"(continued from footnote 6) provided that each such Closing Date Contingent Option shall only receive the excess of the sum of (x) the Cash Consideration plus (y) the Milestone Payment over the applicable exercise price of such Closing Date Contingent Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Stock Option having an exercise price equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and the Milestone Payment (each such option, a \"Closing Date Contingent Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Closing Date Contingent Option, and each holder of such Closing Date Contingent Option is entitled to receive (without interest) an amount in cash (less any applicable tax withholdings) equal to the product of (i) the total number of shares of the Issuer's Common Stock subject to such Closing Date Contingent Option immediately prior to the Effective Time multiplied by (ii) the cash payment a holder of one CVR would receive, and when such payments are made to the holders of CVRs (without regard to vesting);"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"(continued from footnote 6) provided that each such Closing Date Contingent Option shall only receive the excess of the sum of (x) the Cash Consideration plus (y) the Milestone Payment over the applicable exercise price of such Closing Date Contingent Option."}],"balance_after":0,"derivative":{"exercise_price":12.75,"underlying":"Common Stock","underlying_shares":526000},"source":{"system":"sec-edgar","filing":"0000950170-25-099260","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025099260/ownership.xml","form_type":"4"}},{"id":1080727,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T21:15:24.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":431988,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":8.24,"underlying":"Common Stock","underlying_shares":431988},"source":{"system":"sec-edgar","filing":"0000950170-25-099260","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025099260/ownership.xml","form_type":"4"}},{"id":1080726,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T21:15:24.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75105,"ownership":{"direct":false,"nature":"Sekar Kathiresan 2023 Annuity Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":2.87,"underlying":"Common Stock","underlying_shares":75105},"source":{"system":"sec-edgar","filing":"0000950170-25-099260","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025099260/ownership.xml","form_type":"4"}},{"id":1080725,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T21:15:24.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500203,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":2.87,"underlying":"Common Stock","underlying_shares":500203},"source":{"system":"sec-edgar","filing":"0000950170-25-099260","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025099260/ownership.xml","form_type":"4"}},{"id":1080724,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T21:15:24.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":167425,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":1.39,"underlying":"Common Stock","underlying_shares":167425},"source":{"system":"sec-edgar","filing":"0000950170-25-099260","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025099260/ownership.xml","form_type":"4"}},{"id":1080723,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T21:15:24.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":138995,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":1.39,"underlying":"Common Stock","underlying_shares":138995},"source":{"system":"sec-edgar","filing":"0000950170-25-099260","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025099260/ownership.xml","form_type":"4"}},{"id":1080722,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-28T21:15:24.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":99000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested Restricted Stock Unit (\"RSU\") that is outstanding immediately prior to the Effective Time was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any RSU, and each such holder of such RSU received (without interest) (x) an amount in cash (less any applicable tax withholdings) equal to the product of the Cash Consideration multiplied by the total number of Shares subject to such RSU and (y) one CVR for each RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested Restricted Stock Unit (\"RSU\") that is outstanding immediately prior to the Effective Time was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any RSU, and each such holder of such RSU received (without interest) (x) an amount in cash (less any applicable tax withholdings) equal to the product of the Cash Consideration multiplied by the total number of Shares subject to such RSU and (y) one CVR for each RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested Restricted Stock Unit (\"RSU\") that is outstanding immediately prior to the Effective Time was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any RSU, and each such holder of such RSU received (without interest) (x) an amount in cash (less any applicable tax withholdings) equal to the product of the Cash Consideration multiplied by the total number of Shares subject to such RSU and (y) one CVR for each RSU."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":99000},"source":{"system":"sec-edgar","filing":"0000950170-25-099260","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025099260/ownership.xml","form_type":"4"}},{"id":1080721,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-28T21:15:24.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":120000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested Restricted Stock Unit (\"RSU\") that is outstanding immediately prior to the Effective Time was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any RSU, and each such holder of such RSU received (without interest) (x) an amount in cash (less any applicable tax withholdings) equal to the product of the Cash Consideration multiplied by the total number of Shares subject to such RSU and (y) one CVR for each RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested Restricted Stock Unit (\"RSU\") that is outstanding immediately prior to the Effective Time was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any RSU, and each such holder of such RSU received (without interest) (x) an amount in cash (less any applicable tax withholdings) equal to the product of the Cash Consideration multiplied by the total number of Shares subject to such RSU and (y) one CVR for each RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested Restricted Stock Unit (\"RSU\") that is outstanding immediately prior to the Effective Time was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any RSU, and each such holder of such RSU received (without interest) (x) an amount in cash (less any applicable tax withholdings) equal to the product of the Cash Consideration multiplied by the total number of Shares subject to such RSU and (y) one CVR for each RSU."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000950170-25-099260","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025099260/ownership.xml","form_type":"4"}},{"id":1080720,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T21:15:24.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":6.01,"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000950170-25-099260","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025099260/ownership.xml","form_type":"4"}},{"id":1080719,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T21:15:24.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":488000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":6.01,"underlying":"Common Stock","underlying_shares":488000},"source":{"system":"sec-edgar","filing":"0000950170-25-099260","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025099260/ownership.xml","form_type":"4"}},{"id":1080718,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-28T21:15:24.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":240997,"ownership":{"direct":false,"nature":"Kathiresan Family 2021 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the \"Milestone Payment\"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the \"Milestone Payment\"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-099260","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025099260/ownership.xml","form_type":"4"}},{"id":1080717,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-28T21:15:24.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":110997,"ownership":{"direct":false,"nature":"Sekar Kathiresan 2021 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the \"Milestone Payment\"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the \"Milestone Payment\"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-099260","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025099260/ownership.xml","form_type":"4"}},{"id":1080716,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-28T21:15:24.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":348431,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the \"Milestone Payment\"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 1,745 shares of the Company's common stock acquired in 2025 under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the \"Milestone Payment\"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-099260","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025099260/ownership.xml","form_type":"4"}},{"id":1119904,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:51:29.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":136681,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2025 with respect to 136,681 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":136681,"derivative":{"exercise_price":3.36,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":136681},"source":{"system":"sec-edgar","filing":"0000950170-25-083310","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025083310/ownership.xml","form_type":"4"}},{"id":1180047,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-04-03T21:00:19.000Z","date":"2025-04-01","kind":"exercise","planned":true,"acquired":false,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 14, 2024, the reporting person was granted 132,000 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2025 and the remainder vesting in equal annual installments until April 1, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 14, 2024, the reporting person was granted 132,000 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2025 and the remainder vesting in equal annual installments until April 1, 2028."}],"balance_after":99000,"derivative":{"underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0000950170-25-050563","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025050563/ownership.xml","form_type":"4"}},{"id":1180046,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-03T21:00:19.000Z","date":"2025-04-02","kind":"sale","planned":true,"acquired":false,"shares":9822,"price":4.15,"value":40761.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on March 18, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person."}],"balance_after":346686,"source":{"system":"sec-edgar","filing":"0000950170-25-050563","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025050563/ownership.xml","form_type":"4"}},{"id":1180045,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-03T21:00:19.000Z","date":"2025-04-01","kind":"exercise","planned":true,"acquired":true,"shares":33000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."}],"balance_after":356508,"source":{"system":"sec-edgar","filing":"0000950170-25-050563","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025050563/ownership.xml","form_type":"4"}},{"id":1305396,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-10T14:00:07.000Z","date":"2025-01-08","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on January 8, 2025. 100% of the shares underlying the option will vest immediately if and when the last quoted trading price per share of the Company's common stock on the Nasdaq Global Select Market is equal to or greater than $20.00 for at least 15 consecutive trading days on or prior to the second anniversary of the grant date."}],"balance_after":150000,"derivative":{"exercise_price":6.01,"expiration_date":"2035-01-07","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000950170-25-003854","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025003854/ownership.xml","form_type":"4"}},{"id":1305395,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-10T14:00:07.000Z","date":"2025-01-08","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 8, 2025, the reporting person was granted restricted stock units, vesting in three equal annual installments, beginning on April 1, 2026, and the remaining two installments vesting on April 1, 2027 and April 1, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On January 8, 2025, the reporting person was granted restricted stock units, vesting in three equal annual installments, beginning on April 1, 2026, and the remaining two installments vesting on April 1, 2027 and April 1, 2028."}],"balance_after":120000,"derivative":{"underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000950170-25-003854","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025003854/ownership.xml","form_type":"4"}},{"id":1305394,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-10T14:00:07.000Z","date":"2025-01-08","kind":"grant","planned":false,"acquired":true,"shares":488000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 8, 2025. 25% of the shares underlying the option will vest on January 8, 2026, and the remainder are scheduled to vest in equal monthly installments thereafter until January 8, 2029."}],"balance_after":488000,"derivative":{"exercise_price":6.01,"expiration_date":"2035-01-07","underlying":"Common Stock","underlying_shares":488000},"source":{"system":"sec-edgar","filing":"0000950170-25-003854","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017025003854/ownership.xml","form_type":"4"}},{"id":1343193,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-04T21:30:05.000Z","date":"2024-12-04","kind":"gift","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Sekar Kathiresan 2021 Irrevocable Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 4, 2024, the reporting person transferred 30,000 shares of Verve Therapeutics, Inc. (the \"Company\") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On December 4, 2024, the reporting person transferred 30,000 shares of Verve Therapeutics, Inc. (the \"Company\") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust."}],"balance_after":110997,"source":{"system":"sec-edgar","filing":"0000950170-24-133290","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017024133290/ownership.xml","form_type":"4"}},{"id":1343192,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-04T21:30:05.000Z","date":"2024-12-04","kind":"gift","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 4, 2024, the reporting person transferred 30,000 shares of Verve Therapeutics, Inc. (the \"Company\") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,380 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan."}],"balance_after":323508,"source":{"system":"sec-edgar","filing":"0000950170-24-133290","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017024133290/ownership.xml","form_type":"4"}},{"id":1463365,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-07-02T11:30:03.000Z","date":"2024-06-28","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024."}],"balance_after":215308,"derivative":{"exercise_price":2.87,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-080012","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017024080012/ownership.xml","form_type":"4"}},{"id":1463364,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-02T11:30:03.000Z","date":"2024-06-28","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":2.87,"value":86100.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 4,918 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan."}],"balance_after":351128,"source":{"system":"sec-edgar","filing":"0000950170-24-080012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017024080012/ownership.xml","form_type":"4"}},{"id":1490277,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T00:04:30.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":102225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":102225,"derivative":{"exercise_price":6.79,"expiration_date":"2034-06-02","underlying":"Common Stock","underlying_shares":102225},"source":{"system":"sec-edgar","filing":"0000950170-24-069557","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017024069557/ownership.xml","form_type":"4"}},{"id":1638542,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-16T21:30:29.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":132000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028."}],"balance_after":132000,"derivative":{"underlying":"Common Stock","underlying_shares":132000},"source":{"system":"sec-edgar","filing":"0000950170-24-016423","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017024016423/ownership.xml","form_type":"4"}},{"id":1638541,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-16T21:30:29.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":526000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028."}],"balance_after":526000,"derivative":{"exercise_price":12.75,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":526000},"source":{"system":"sec-edgar","filing":"0000950170-24-016423","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000095017024016423/ownership.xml","form_type":"4"}},{"id":1872200,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T22:39:31.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":66055,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 31, 2023 with respect to 66,055 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":66055,"derivative":{"exercise_price":11.14,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":66055},"source":{"system":"sec-edgar","filing":"0001209191-23-033438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919123033438/doc4.xml","form_type":"4"}},{"id":2011253,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-16T22:00:26.000Z","date":"2023-02-14","kind":"grant","acquired":true,"shares":550200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on February 14, 2023. 25% of the shares underlying the option will vest on February 14, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2027."}],"balance_after":550200,"derivative":{"exercise_price":21.76,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":550200},"source":{"system":"sec-edgar","filing":"0001209191-23-010123","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919123010123/doc4.xml","form_type":"4"}},{"id":2142367,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-10-05T21:00:21.000Z","date":"2022-10-03","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The remaining shares underlying this option, which was granted on April 15, 2019, vest in equal monthly installments until March 25, 2024."}],"balance_after":138995,"derivative":{"exercise_price":1.39,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-052799","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122052799/doc4.xml","form_type":"4"}},{"id":2142366,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-05T21:00:21.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":9904,"price":34.9723,"value":346365.6592,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.61 to $35.50, inclusive."}],"balance_after":317839,"source":{"system":"sec-edgar","filing":"0001209191-22-052799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122052799/doc4.xml","form_type":"4"}},{"id":2142365,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-05T21:00:21.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":11185,"price":34.1296,"value":381739.576,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.59 to $34.59, inclusive."}],"balance_after":327743,"source":{"system":"sec-edgar","filing":"0001209191-22-052799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122052799/doc4.xml","form_type":"4"}},{"id":2142364,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-05T21:00:21.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":28911,"price":33.0157,"value":954516.9027,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.59 to $33.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4) of this Form 4."}],"balance_after":338928,"source":{"system":"sec-edgar","filing":"0001209191-22-052799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122052799/doc4.xml","form_type":"4"}},{"id":2142363,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-05T21:00:21.000Z","date":"2022-10-03","kind":"exercise","acquired":true,"shares":50000,"price":1.39,"value":69500.0,"ownership":{"direct":true},"balance_after":367839,"source":{"system":"sec-edgar","filing":"0001209191-22-052799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122052799/doc4.xml","form_type":"4"}},{"id":2188277,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-11T21:00:28.000Z","date":"2022-08-10","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023."}],"balance_after":167425,"derivative":{"exercise_price":1.39,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-045447","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122045447/doc4.xml","form_type":"4"}},{"id":2188276,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-08-11T21:00:28.000Z","date":"2022-08-10","kind":"sale","acquired":false,"shares":50000,"price":29.9,"value":1495000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022."}],"balance_after":317839,"source":{"system":"sec-edgar","filing":"0001209191-22-045447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122045447/doc4.xml","form_type":"4"}},{"id":2188275,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-08-11T21:00:28.000Z","date":"2022-08-10","kind":"exercise","acquired":true,"shares":50000,"price":1.39,"value":69500.0,"ownership":{"direct":true},"balance_after":367839,"source":{"system":"sec-edgar","filing":"0001209191-22-045447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122045447/doc4.xml","form_type":"4"}},{"id":2201409,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to\nBuy)","published_at":"2022-07-27T22:57:52.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":71881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments after July 25, 2022, subject to the reporting person's continued service with the Issuer through each vesting date."}],"balance_after":71881,"derivative":{"exercise_price":20.46,"expiration_date":"2032-07-24","underlying":"Common Stock","underlying_shares":71881},"source":{"system":"sec-edgar","filing":"0000899243-22-026903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924322026903/doc4.xml","form_type":"4"}},{"id":2204015,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-21T21:00:32.000Z","date":"2022-07-19","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023."}],"balance_after":217425,"derivative":{"exercise_price":1.39,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-042871","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122042871/doc4.xml","form_type":"4"}},{"id":2204014,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-21T21:00:32.000Z","date":"2022-07-19","kind":"sale","acquired":false,"shares":50000,"price":29.9,"value":1495000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022."}],"balance_after":317839,"source":{"system":"sec-edgar","filing":"0001209191-22-042871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122042871/doc4.xml","form_type":"4"}},{"id":2204013,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-21T21:00:32.000Z","date":"2022-07-19","kind":"exercise","acquired":true,"shares":50000,"price":1.39,"value":69500.0,"ownership":{"direct":true},"balance_after":367839,"source":{"system":"sec-edgar","filing":"0001209191-22-042871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122042871/doc4.xml","form_type":"4"}},{"id":2207137,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-15T21:00:27.000Z","date":"2022-07-12","kind":"gift","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Sekar Kathiresan 2022 Annuity Trust"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares underlying the option being transferred were fully vested as of the date of transfer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"On July 12, 2022, the reporting person transferred an employee stock option to purchase 160,000 shares of common stock of the Company to a grantor retained annuity trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust."}],"balance_after":300000,"derivative":{"exercise_price":2.87,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-22-042265","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122042265/doc4.xml","form_type":"4"}},{"id":2207136,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-15T21:00:27.000Z","date":"2022-07-12","kind":"gift","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Sekar Kathiresan 2022 Annuity Trust"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares underlying the option being transferred were fully vested as of the date of transfer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On July 12, 2022, the reporting person transferred an employee stock option to purchase 140,000 shares of common stock of the Company to a grantor retained annuity trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust."}],"balance_after":140000,"derivative":{"exercise_price":8.24,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001209191-22-042265","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122042265/doc4.xml","form_type":"4"}},{"id":2207135,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-15T21:00:27.000Z","date":"2022-07-12","kind":"gift","acquired":false,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On July 12, 2022, the reporting person transferred an employee stock option to purchase 160,000 shares of common stock of the Company to a grantor retained annuity trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024."}],"balance_after":445308,"derivative":{"exercise_price":2.87,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-22-042265","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122042265/doc4.xml","form_type":"4"}},{"id":2207134,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-15T21:00:27.000Z","date":"2022-07-12","kind":"gift","acquired":false,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On July 12, 2022, the reporting person transferred an employee stock option to purchase 140,000 shares of common stock of the Company to a grantor retained annuity trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The remaining shares underlying this option, which was granted on February 12, 2021, vest in equal monthly installments until February 1, 2025."}],"balance_after":291988,"derivative":{"exercise_price":8.24,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001209191-22-042265","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122042265/doc4.xml","form_type":"4"}},{"id":2207133,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-15T21:00:27.000Z","date":"2022-07-07","kind":"gift","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Kathiresan Family 2021 Irrevocable Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 7, 2022, the reporting person transferred 160,000 shares of Verve Therapeutics, Inc. (the \"Company\") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On July 7, 2022, the reporting person transferred 160,000 shares of Verve Therapeutics, Inc. (the \"Company\") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust."}],"balance_after":240997,"source":{"system":"sec-edgar","filing":"0001209191-22-042265","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122042265/doc4.xml","form_type":"4"}},{"id":2207132,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-15T21:00:27.000Z","date":"2022-07-07","kind":"gift","acquired":false,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 7, 2022, the reporting person transferred 160,000 shares of Verve Therapeutics, Inc. (the \"Company\") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 314 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan."}],"balance_after":317839,"source":{"system":"sec-edgar","filing":"0001209191-22-042265","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000120919122042265/doc4.xml","form_type":"4"}},{"id":2321751,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-22T11:41:17.000Z","date":"2022-03-18","kind":"exercise","acquired":false,"shares":69674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024."}],"balance_after":605308,"derivative":{"exercise_price":2.87,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":69674},"source":{"system":"sec-edgar","filing":"0000899243-22-011767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924322011767/doc4.xml","form_type":"4"}},{"id":2321750,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-22T11:41:17.000Z","date":"2022-03-18","kind":"exercise","acquired":true,"shares":69674,"price":2.87,"value":199964.38,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,315 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan."}],"balance_after":477525,"source":{"system":"sec-edgar","filing":"0000899243-22-011767","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924322011767/doc4.xml","form_type":"4"}},{"id":2394778,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-15T13:58:14.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":332000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on February 11, 2022. 25% of the shares underlying the option will vest on February 11, 2023, and the remainder are scheduled to vest in equal monthly installments thereafter until February 11, 2026."}],"balance_after":332000,"derivative":{"exercise_price":30.94,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":332000},"source":{"system":"sec-edgar","filing":"0000899243-22-006365","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924322006365/doc4.xml","form_type":"4"}},{"id":2441823,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T21:36:22.000Z","date":"2022-01-04","kind":"exercise","acquired":false,"shares":1870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023."}],"balance_after":267425,"derivative":{"exercise_price":1.39,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":1870},"source":{"system":"sec-edgar","filing":"0000899243-22-001203","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924322001203/doc4.xml","form_type":"4"}},{"id":2441822,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-06T21:36:22.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":1870,"price":39.9,"value":74613.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021."}],"balance_after":406536,"source":{"system":"sec-edgar","filing":"0000899243-22-001203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924322001203/doc4.xml","form_type":"4"}},{"id":2441821,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-06T21:36:22.000Z","date":"2022-01-04","kind":"exercise","acquired":true,"shares":1870,"price":1.39,"value":2599.3,"ownership":{"direct":true},"balance_after":408406,"source":{"system":"sec-edgar","filing":"0000899243-22-001203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924322001203/doc4.xml","form_type":"4"}},{"id":2457248,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-12-29T21:38:28.000Z","date":"2021-12-28","kind":"exercise","acquired":false,"shares":6693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023."}],"balance_after":269295,"derivative":{"exercise_price":1.39,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":6693},"source":{"system":"sec-edgar","filing":"0000899243-21-050032","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321050032/doc4.xml","form_type":"4"}},{"id":2457247,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-12-29T21:38:28.000Z","date":"2021-12-27","kind":"exercise","acquired":false,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023."}],"balance_after":275988,"derivative":{"exercise_price":1.39,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000899243-21-050032","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321050032/doc4.xml","form_type":"4"}},{"id":2457246,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-29T21:38:28.000Z","date":"2021-12-28","kind":"sale","acquired":false,"shares":6693,"price":39.9,"value":267050.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021."}],"balance_after":406536,"source":{"system":"sec-edgar","filing":"0000899243-21-050032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321050032/doc4.xml","form_type":"4"}},{"id":2457245,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-29T21:38:28.000Z","date":"2021-12-28","kind":"exercise","acquired":true,"shares":6693,"price":1.39,"value":9303.27,"ownership":{"direct":true},"balance_after":413229,"source":{"system":"sec-edgar","filing":"0000899243-21-050032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321050032/doc4.xml","form_type":"4"}},{"id":2457244,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-29T21:38:28.000Z","date":"2021-12-27","kind":"sale","acquired":false,"shares":770,"price":42.2106,"value":32502.162,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.84 to $42.49, inclusive."}],"balance_after":406536,"source":{"system":"sec-edgar","filing":"0000899243-21-050032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321050032/doc4.xml","form_type":"4"}},{"id":2457243,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-29T21:38:28.000Z","date":"2021-12-27","kind":"sale","acquired":false,"shares":4787,"price":41.2431,"value":197430.7197,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.86 to $41.74, inclusive."}],"balance_after":407306,"source":{"system":"sec-edgar","filing":"0000899243-21-050032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321050032/doc4.xml","form_type":"4"}},{"id":2457242,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-29T21:38:28.000Z","date":"2021-12-27","kind":"sale","acquired":false,"shares":36443,"price":40.0228,"value":1458550.9004,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.90 to $40.85, inclusive. The Reporting Person    undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4) of this Form 4."}],"balance_after":412093,"source":{"system":"sec-edgar","filing":"0000899243-21-050032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321050032/doc4.xml","form_type":"4"}},{"id":2457241,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-29T21:38:28.000Z","date":"2021-12-27","kind":"exercise","acquired":true,"shares":42000,"price":1.39,"value":58380.0,"ownership":{"direct":true},"balance_after":448536,"source":{"system":"sec-edgar","filing":"0000899243-21-050032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321050032/doc4.xml","form_type":"4"}},{"id":2458719,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-12-27T23:08:02.000Z","date":"2021-12-23","kind":"exercise","acquired":false,"shares":57000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023."}],"balance_after":317988,"derivative":{"exercise_price":1.39,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":57000},"source":{"system":"sec-edgar","filing":"0000899243-21-049812","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321049812/doc4.xml","form_type":"4"}},{"id":2458718,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-12-27T23:08:02.000Z","date":"2021-12-22","kind":"exercise","acquired":false,"shares":57000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023."}],"balance_after":374988,"derivative":{"exercise_price":1.39,"expiration_date":"2029-04-14","underlying":"Common Stock","underlying_shares":57000},"source":{"system":"sec-edgar","filing":"0000899243-21-049812","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321049812/doc4.xml","form_type":"4"}},{"id":2458717,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-27T23:08:02.000Z","date":"2021-12-23","kind":"sale","acquired":false,"shares":57000,"price":39.9,"value":2274300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021."}],"balance_after":406536,"source":{"system":"sec-edgar","filing":"0000899243-21-049812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321049812/doc4.xml","form_type":"4"}},{"id":2458716,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-27T23:08:02.000Z","date":"2021-12-23","kind":"exercise","acquired":true,"shares":57000,"price":1.39,"value":79230.0,"ownership":{"direct":true},"balance_after":463536,"source":{"system":"sec-edgar","filing":"0000899243-21-049812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321049812/doc4.xml","form_type":"4"}},{"id":2458715,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-27T23:08:02.000Z","date":"2021-12-22","kind":"sale","acquired":false,"shares":3269,"price":39.7783,"value":130035.2627,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.74 to $39.98, inclusive."}],"balance_after":406536,"source":{"system":"sec-edgar","filing":"0000899243-21-049812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321049812/doc4.xml","form_type":"4"}},{"id":2458714,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-27T23:08:02.000Z","date":"2021-12-22","kind":"sale","acquired":false,"shares":31139,"price":39.0564,"value":1216177.2396,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.70, inclusive."}],"balance_after":409805,"source":{"system":"sec-edgar","filing":"0000899243-21-049812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321049812/doc4.xml","form_type":"4"}},{"id":2458713,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-27T23:08:02.000Z","date":"2021-12-22","kind":"sale","acquired":false,"shares":16718,"price":38.3139,"value":640531.7802,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.81 to $38.76, inclusive."}],"balance_after":440944,"source":{"system":"sec-edgar","filing":"0000899243-21-049812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321049812/doc4.xml","form_type":"4"}},{"id":2458712,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-27T23:08:02.000Z","date":"2021-12-22","kind":"sale","acquired":false,"shares":5874,"price":37.3782,"value":219559.5468,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.84 to $37.73, inclusive. The Reporting Person    undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) of this Form 4."}],"balance_after":457662,"source":{"system":"sec-edgar","filing":"0000899243-21-049812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321049812/doc4.xml","form_type":"4"}},{"id":2458711,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-27T23:08:02.000Z","date":"2021-12-22","kind":"exercise","acquired":true,"shares":57000,"price":1.39,"value":79230.0,"ownership":{"direct":true},"balance_after":463536,"source":{"system":"sec-edgar","filing":"0000899243-21-049812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321049812/doc4.xml","form_type":"4"}},{"id":2661543,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-21T22:20:58.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":53998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 17, 2021. 25% of the shares underlying the option will vest on June 17, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until June 17, 2025."}],"balance_after":53998,"derivative":{"exercise_price":19,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":53998},"source":{"system":"sec-edgar","filing":"0000899243-21-025070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321025070/doc4.xml","form_type":"4"}},{"id":2661542,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":75000,"kind":"person","name":"Kathiresan Sekar","position":1,"cik":"0001864112","reported_name":"Kathiresan Sekar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-06-21T22:20:58.000Z","date":"2021-06-21","kind":"purchase","acquired":true,"shares":2500,"price":19,"value":47500.0,"ownership":{"direct":true},"balance_after":406536,"source":{"system":"sec-edgar","filing":"0000899243-21-025070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864112/000089924321025070/doc4.xml","form_type":"4"}}]}